AUTERI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 578
EU - Europa 459
AS - Asia 197
AF - Africa 42
SA - Sud America 3
OC - Oceania 1
Totale 1280
Nazione #
US - Stati Uniti d'America 574
GB - Regno Unito 119
SE - Svezia 117
VN - Vietnam 94
IT - Italia 92
DE - Germania 54
IN - India 52
CN - Cina 41
TG - Togo 36
RU - Federazione Russa 27
FR - Francia 23
EE - Estonia 9
ZA - Sudafrica 6
BE - Belgio 4
CA - Canada 4
IR - Iran 4
UA - Ucraina 4
CH - Svizzera 3
PL - Polonia 3
TR - Turchia 3
BR - Brasile 2
FI - Finlandia 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
HR - Croazia 1
HU - Ungheria 1
JP - Giappone 1
SG - Singapore 1
Totale 1280
Città #
Southend 111
Dong Ket 93
Fairfield 69
Princeton 54
Chandler 45
Ashburn 43
Lomé 36
Houston 35
Wilmington 29
Woodbridge 29
Redmond 27
Seattle 27
Bologna 26
Ann Arbor 22
Cambridge 20
Nanjing 16
Berlin 14
Westminster 14
Milan 13
Monheim 9
Des Moines 7
Beijing 6
Medford 6
Saint Petersburg 6
Fremont 5
Norwalk 5
San Diego 5
Boydton 4
Brussels 4
Falls Church 4
Leawood 4
Migliarino 4
Redwood City 4
Shenyang 4
Toronto 4
Andover 3
Changsha 3
Nanchang 3
Rome 3
San Francisco 3
Hefei 2
Helsinki 2
Kuban 2
Taizhou 2
Torino 2
Zanjan 2
Abano Terme 1
Bagnacavallo 1
Budapest 1
Canberra 1
Capo D'orlando 1
Casalecchio di Reno 1
Catanzaro 1
Changchun 1
Charlotte 1
Chicago 1
Clearwater 1
Cutrofiano 1
Dearborn 1
Delhi 1
Duino 1
Formigine 1
Haikou 1
Hanoi 1
Hebei 1
Izhevsk 1
Leeds 1
Leipzig 1
Melzo 1
Muizenberg 1
Napoli 1
Padova 1
Parma 1
Pavia 1
Poznan 1
Rende 1
Sacramento 1
Singapore 1
São Paulo 1
Taiyuan 1
Teramo 1
Tokyo 1
Tula 1
Varese 1
Warsaw 1
Westbury-sub-mendip 1
Zelenograd 1
Zhengzhou 1
Totale 873
Nome #
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 96
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 92
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 91
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 91
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 89
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 86
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 83
null 68
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 67
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 62
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 54
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 52
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 47
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 44
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 39
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 37
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 34
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 33
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 32
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 32
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 30
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 29
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 21
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 19
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 17
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 12
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 10
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 7
Totale 1374
Categoria #
all - tutte 2252
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2252


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182 0000 00 00 1010
2018/201960 3100 13 027 19312
2019/2020244 488013 2219 2538 2721176
2020/2021295 371482 217 723 5038124
2021/2022559 8172451 3222 1155 1954159107
2022/2023214 571014610 00 00 0000
Totale 1374